Naver Expands AI Healthcare Ecosystem... Advances Clinical Trial Platform

Investment and Technology Collaboration with JNP Medi

Naver is leveraging artificial intelligence (AI) technology to expand its healthcare ecosystem and take on the global market.

Choi Inhyuk, CEO of Naver Tech Business (right), and Jung Kwonho, CEO of JNP Medi, are taking a commemorative photo after signing a comprehensive business agreement in the digital healthcare sector at Naver Building 1784. Photo by Naver

On August 13, Naver announced that it had signed a "comprehensive business agreement in the digital healthcare sector" with JNP Medi. JNP Medi is a leading Korean digital healthcare company that provides clinical trial data platforms and supports contract research organization (CRO) services for pharmaceutical, biotech, and medical device companies.

Naver has decided to invest in JNP Medi and collaborate to advance AI technology and clinical trial platforms. In particular, Naver will work with JNP Medi to manage clinical trial data, which is considered a national strategic asset, and to achieve technological independence. By combining AI technology, the two companies aim to build digital clinical trial capabilities necessary for global expansion.

Choi Inhyeok, CEO of Naver Tech Business, said, "Through this collaboration, both companies plan to jointly identify and invest in promising digital healthcare companies at home and abroad, supporting their global expansion and mutual growth," adding, "We will establish a digital transformation infrastructure for the entire domestic healthcare ecosystem."

Healthcare is a key focus area for Naver, which has continued to invest in technology. Previously, Naver introduced "Smart Survey," which automatically converts patient histories into medical terminology and records them in electronic medical records (EMR), as well as "Patient Summary," which uses AI summarization technology to organize and analyze past examination results.

In addition, since 2017, Naver D2SF has been investing in promising healthcare startups. As of this month, approximately 18% of its total investment portfolio consists of healthcare startups.